ANCA-associated vasculitis

AAV · R&I · 1 drugs · 1 indications

Competitive Landscape (1 drugs)

Drug	Company	Mechanism	Modality	Route	Stage
TAVNEOS	AMGN	C5a receptor antagonist (oral)	Small molecule	Oral	APPROVED

Indications (1)

TAVNEOS APPROVED

Data from Supabase · Updated 2026-03-24